Trademark applications and grants for Fulcrum Therapeutics Inc. Fulcrum Therapeutics Inc has 23 trademark applications. The latest application filed is for "MEVMYNTO"
Patent Application | Date |
---|---|
P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD 20220282254 - 17/741993 Cacace; Angela Marie ;   et al. | 2022-09-08 |
MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS 20220160686 - 17/178637 Efremov; Ivan Viktorovich ;   et al. | 2022-05-26 |
P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD 20220133704 - 17/525394 Cacace; Angela Marie ;   et al. | 2022-05-05 |
COMPOSITIONS AND METHODS FOR INCREASING FETAL HEMOGLOBIN AND TREATING SICKLE CELL DISEASE 20220017908 - 17/295782 Rahl; Peter ;   et al. | 2022-01-20 |
P38 KINASE INHIBITORS REDUCE DUX4 AND DOWNSTREAM GENE EXPRESSION FOR THE TREATMENT OF FSHD 20200383963 - 16/748217 CACACE; Angela Marie ;   et al. | 2020-12-10 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.